Pivotal trial of V 503 (Merck) for HPV has met primary endpoints
Merck has announced that the pivotal efficacy trial for V 503 (HPV vaccine) is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V 503 to the FDA in 2013. The study evaluated the efficacy, immunogenicity and safety of V 503 in females 16-26 years of age. Merck plans to present results from this study, as well as other results from the Phase III clinical program for V 503, at the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) congress in November.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins